Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
1985-7-18
pubmed:abstractText
We studied the human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus (HTLV-III/LAV) antibody status of 234 factor VIII concentrate recipients, 36 factor IX concentrate recipients, 69 long-term recipients of frozen packed red blood cells, and 47 persons not receiving routine transfusion therapy. Factor VIII concentrate recipients had a significantly higher rate of seropositivity (74%) than any other group. Factor IX concentrate recipients had a significantly higher rate (39%) than recipients of frozen packed red blood cells (4%) or nontransfused persons (4%). In factor VIII concentrate recipients, HTLV-III/LAV seropositivity was significantly associated with more severe hemophilia, greater factor dosage, elevated immunoglobulin and immune complex levels, lower T-helper lymphocyte numbers, and lower ratios of T-helper to T-suppressor lymphocytes. For factor IX concentrate recipients, seropositivity was associated with more severe hemophilia. Antibody-positive factor IX concentrate recipients had a lower rate of seropositivity to HTLV-III/LAV p41 membrane antigen than did antibody-positive factor VIII concentrate recipients, but factor VIII and factor IX concentrate recipients had similar rates of seropositivity to core antigens. We conclude that both factor VIII and factor IX concentrates may transmit HTLV-III/LAV. For factor VIII recipients, HTLV-III/LAV seropositivity is associated with altered immune test results.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0098-7484
pubmed:author
pubmed:issnType
Print
pubmed:day
21
pubmed:volume
253
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3409-15
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:2987559-Adolescent, pubmed-meshheading:2987559-Adult, pubmed-meshheading:2987559-Antibodies, Viral, pubmed-meshheading:2987559-Antigen-Antibody Complex, pubmed-meshheading:2987559-Austria, pubmed-meshheading:2987559-Blood Coagulation Factors, pubmed-meshheading:2987559-Blood Transfusion, pubmed-meshheading:2987559-Child, pubmed-meshheading:2987559-Deltaretrovirus, pubmed-meshheading:2987559-Erythrocyte Transfusion, pubmed-meshheading:2987559-Factor VIII, pubmed-meshheading:2987559-Female, pubmed-meshheading:2987559-Georgia, pubmed-meshheading:2987559-Hemophilia A, pubmed-meshheading:2987559-Humans, pubmed-meshheading:2987559-Immunoglobulins, pubmed-meshheading:2987559-Leukocyte Count, pubmed-meshheading:2987559-Lymphocytes, pubmed-meshheading:2987559-Male, pubmed-meshheading:2987559-Middle Aged, pubmed-meshheading:2987559-New York City, pubmed-meshheading:2987559-Retroviridae Infections, pubmed-meshheading:2987559-Serologic Tests, pubmed-meshheading:2987559-United States
pubmed:year
1985
pubmed:articleTitle
Human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus antibody. Association with hemophiliacs' immune status and blood component usage.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S.